Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival si…
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
This protective measure underscores the significance and value of our brand in the field of spine surgery, demonstrating…
Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear road…
At ECR 2024, Ziehm Imaging, the innovation leader for mobile C-arms, will present its extended product line for the comp…
Eight pre-selected start-ups from medicine and life sciences pitched their business ideas at the 13th BioAngels Pitch Da…
“Those who have worn the HoloLens 2 in the operating room see it as a true game-changer. They have the planning images i…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
Increasing geriatric population, growing preference for minimally invasive procedures like annuloplasty and transcathete…